International Clinical Trials in Obstetrics/Gynecology

Albania

• Post-Menopausal Osteoporosis: BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
  Tirana; Research Site:
  
  

Algeria

• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Alger; Research Site:
  
  

Argentina

• Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
  Buenos Aires; Hospital Britanico De Buenos Aires
  
  
• Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
  Buenos Aires; Corporacion Medica De General San Martin
  
  
• Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
  Capital Federal; Hospital Italiano De Buenos Aires
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Cordoba; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Mar Del Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Mendoza; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  San Martin; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Santa Fe; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Rosario; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Tucuman; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Chaco-Resistencia; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Córdoba; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Mendoza; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Rosario; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Rosario; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Buenos Aires ; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  La Plata; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Pilar; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Santa Fe; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Buenos Aires ; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Buenos Aires ; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Cordoba; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Santa Fe; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Buenos Aires ; Research Site:
  
  

Australia

• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Liverpool; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Lismore; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Port Macquarie; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Waratah; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Wollongong; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Darlinghurst; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  East Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Frankston; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Lismore; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Maroochydore; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Richmond; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  St. Leonards; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wodonga; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Frankston; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Heidelberg; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Hobart; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Malvern; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Wodonga; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Southport; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Brisbane; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Geelong; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Patients With Metastatic Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Adelaide; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Brisbane; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Fitzroy; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Geelong; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Heidelberg; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Malvern; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Melbourne; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Nambour; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Parkville; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Port Macquarie; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  St. Leonards; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Waratah; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wodonga; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wollongong; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Adelaide; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Brisbane; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Campbelltown; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Frankston; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Gosford; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Heidelberg; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Liverpool; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Malvern; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Melbourne; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Milton; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Perth; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  St. Leonards; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Sydney; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Wollongong; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Adelaide; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Fitzroy; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Frankston; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Geelong; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Heidelberg; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Liverpool; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Melbourne; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Parkville; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Perth; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Sydney; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Toowoomba; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Waratah; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wodonga; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
  St. Leonards; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
  Sydney; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Darlinghurst; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Melbourne; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Nedlands; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  St. Leonards; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Sydney; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Adelaide; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Parkville; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Perth; Research Site:
  
  
• Urinary Incontinence: A research study for patients with symptoms of overactive bladder.
  Adelaide, SA; Royal Adelaide Hospital
  
  

Austria

• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Graz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Graz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Bregenz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Dornbirn; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Innsbruck; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Krems; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Leoben; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Linz; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  St Pölten; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wels; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Wiener Neustadt; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Klagenfurt; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Bludesch; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Graz; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Innsbruck; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Leoben; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Salzburg; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wels; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wiener Neustadt; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wolfsberg; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Graz; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Innsbruck; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Klagenfurt; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Kufstein; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Leoben; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Linz; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Oberwart; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Salzburg; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Wels; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Wien; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Bludesch; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Graz; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Innsbruck; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Klagenfurt; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Linz; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Salzburg; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  St Veit an der Glan; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Villach; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Vöcklabruck; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wels; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wien; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Wiener Neustadt; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Bregenz; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Graz; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Innsbruck; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Linz; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Salzburg; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Vöcklabruck; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Wien; Research Site:
  
  

Belgium

• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Bruxelles; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Bruxelles; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Wilrijk; Research Site:
  
  
• Breast Cancer: A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-Negative’ Breast Cancer
  Bruxelles; Cliniques Universitaires Saint-Luc
  
  
• Breast Cancer: A Study of Dasatinib (BMS-354825) in Patients With Advanced ‘Triple-Negative’ Breast Cancer
  Bruxelles; Institut Jules Bordet
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Brasschaat; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Charleroi; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Namur; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With c-erbB2-Positive Metastatic Breast Cancer
  Bruxelles; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Bruxelles; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Namur; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Patients With Metastatic Breast Cancer
  Namur; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Baudour; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Bruxelles; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Hasselt; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sint-Niklaas; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Wilrijk; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Brasschaat; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Charleroi; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Ottignies; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Wilrijk; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Antwerpen; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Baudour; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Bruxelles; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Charleroi; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Kortrijk; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Leuven; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Liege; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Namur; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Oostende; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Verviers; Research Site:
  
  
• Breast Cancer: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
  Bruxelles; Institut Jules Bordet
  
  
• Breast Cancer: Study of Dasatinib (BMS-354825) in Patients with Advanced Estrogen/Progesterone Receptor-Positive (ER+/PR+) or Her2/Neu-Positive (Her2/Neu+) Breast Cancer
  Bruxelles; Cliniques Universitaires Saint-Luc
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Bruxelles; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Leuven; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Wilrijk; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Gent; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Leuven; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
  Merksem; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
  Bruxelles; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Aalst; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Antwerpen; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Braine L'Alleud; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Brugge; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Bruxelles; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Charleroi; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Dinant; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Ekeren; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Genk; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Gent; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Godinne; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Hasselt; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Kortrijk; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Merksem; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Mons; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Oostende; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Roeselare; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Sijsele; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Tournai; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Waremme; Research Site:
  
  
• Post-Menopausal Osteoporosis: BEATRIS study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women with Post-Menopausal Osteoporosis
  Wilrijk; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Bruxelles; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Liege; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Merksem; Research Site:
  
  

Bosnia and Herzegovina

• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Banja Luka; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Tuzla; Research Site:
  
  
• Breast Cancer: A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
  Mostar; Research Site:
  
  
• Breast Cancer: A Study to Assess Xeloda (Capecitabine) in Patients With Locally Advanced or Metastatic Breast Cancer
  Sarajevo; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sarajevo; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Sarajevo; Research Site:
  
  
• Post-Menopausal Osteoporosis: BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
  Banja Luka; Research Site:
  
  
• Post-Menopausal Osteoporosis: BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
  Sarajevo; Research Site:
  
  
• Post-Menopausal Osteoporosis: BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
  Tuzla; Research Site:
  
  

Brazil

• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Barretos; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Florianopolis; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Goiania; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Barretos; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Belo Horizonte; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Florianopolis; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Goiania; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Belo Horizonte; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Campinas; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Curitiba; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Fortaleza; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Goiania; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Ijuí; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Jaú; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Niteroi; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Piracicaba; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Ribeirão Preto; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Salvador; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Vitoria; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Caxias do Sul; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Fortaleza; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Goiania; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Ijuí; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Jaú; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Ribeirão Preto; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Salvador; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Santo Andre; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Santos; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination with Herceptin (Trastuzumab) and Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sorocaba; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Ijuí; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Itajaí; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Jaú; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Santo Andre; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Sorocaba; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Belo Horizonte; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Campinas; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Caxias do Sul; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Florianopolis; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Fortaleza; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Goiania; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Ijuí; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Itajaí; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Jaú; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Lajeado; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Natal; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Niteroi; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Petrópolis; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Porto Alegre; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Ribeirão Preto; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Salvador; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Santo Andre; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Santos; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Sao Paulo; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Sorocaba; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Taguatinga; Research Site:
  
  
• Breast Cancer: A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
  Teresina; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Jaú; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Porto Alegre; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Porto Alegre Rs; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Santo Andre; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Belo Horizonte; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Campinas; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Fortaleza; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Goiania; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Ijuí; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Jaú; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Porto Alegre; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Porto Alegre Rs; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Santo Andre; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Sao Paulo; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Sorocaba; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Porto Alegre; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Rio De Janeiro; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Santo Andre; Research Site:
  
  
• Breast Cancer: This is a multi-national, double-blind, placebo controlled study in patients with locally advanced or metastatic breast cancer.
  Various Cities; SOLTI (Grupo Español de Estudio, Tratamiento y Otras Estrategias Experimentales en Tumores Sólidos)
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Brasilia; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Curitiba; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Goiania; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Porto Alegre; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Rio De Janeiro; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Sao Paulo; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
  Vitoria; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Brasilia; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Sao Paulo; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Vitoria; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
  Sao Paulo; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Campinas; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Curitiba; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Porto Alegre; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Sao Paulo; Research Site:
  
  

Buenos Aires

• Breast Cancer: A Neoadjuvant Study of AC Followed by Ixabepilone or Paclitaxel in Early Stage Breast Cancer That is HER-2 Negative and Estrogen Receptor Negative
  Buenos Aires; Sanatorio Güemes
  
  

Bulgaria

• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Plovdiv; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Sofia; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Varna; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Veliko Tarnovo; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
  Plovdiv; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
  Sofia; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
  Veliko Tarnovo; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Plovdiv; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Sofia; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Stara Zagora; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Plovdiv; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Sofia; Research Site:
  
  

Canada

• Breast Cancer: A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
  Edmonton, AB; Cross Cancer Institute
  
  
• Breast Cancer: A clinical study to evaluate the effect of a new treatment in patients with Prostate or Breast Cancer with Metastatic Bone Disease
  Montreal, QC; Hospital Notre Dame
  
  
• Breast Cancer: A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain in Patients Who are not Candidates for Radiation Therapy
  Toronto, Ontario; Toronto General Hospital
  
  
• Breast Cancer: A PK-Loading Study of q3w Herceptin (Trastuzumab) Monotherapy in Women With HER2 Positive Metastatic Breast Cancer.
  Greenfield Park, QC; Research Site:
  
  
• Breast Cancer: A PK-Loading Study of q3w Herceptin (Trastuzumab) Monotherapy in Women With HER2 Positive Metastatic Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Calgary, AB; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Halifax, NS; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Sudbury, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Calgary, AB; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Edmonton, AB; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Halifax, NS; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Sudbury, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Vancouver, BC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Brampton, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Mississauga, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Newmarket, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Quebec City, QC; Research Center
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Regina, SK; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Sault Ste Marie, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Scarborough, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  St. Catharines, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Surrey, BC; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Windsor, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Brampton, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Edmonton, AB; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Newmarket, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  North Vancouver, BC; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Advanced Breast Cancer
  Thunder Bay, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With HER2-Positive Advanced and/or Metastatic Breast Cancer
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Brampton, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Greenfield Park, QC; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Oshawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) in Women With Metastatic Breast Cancer
  Winnipeg, MB; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Calgary, AB; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Herceptin (Trastuzumab) Monotherapy in Women With Metastatic Breast Cancer
  Winnipeg, MB; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Kingston, ON; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Moncton, NB; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With Metastatic Breast Cancer.
  London, ON; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With Metastatic Breast Cancer.
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With Metastatic Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: A Study of Pertuzumab in Combination With Herceptin in Patients With Metastatic Breast Cancer.
  Vancouver, BC; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Calgary, AB; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Edmonton, AB; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: A Study to Evaluate the Efficacy and Safety of Herceptin (Trastuzumab) in Combination With an Aromatase Inhibitor in Patients With Metastatic Breast Cancer
  Toronto, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Edmonton, AB; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Greenfield Park, QC; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Halifax, NS; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Kingston, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  London, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Moncton, NB; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Oshawa, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Saskatoon, SK; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  St John'S; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Sudbury, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Surrey, BC; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Vancouver, BC; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Windsor, ON; Research Site:
  
  
• Breast Cancer: BEATRICE study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
  Winnipeg, MB; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Brampton, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Calgary, AB; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Edmonton, AB; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Greenfield Park, QC; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Mediciine Hat, AB; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Montreal, QC; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Newmarket, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  North Vancouver, BC; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Ottawa, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  St John'S; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Sudbury, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Toronto, ON; Research Site:
  
  
• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Windsor, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Calgary, AB; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Charlottetown, PE; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Kelowna, BC; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Quebec City, QC; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Regina, SK; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Saskatoon, SK; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Sault Ste Marie, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  St. Catharines, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Surrey, BC; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Toronto, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Vancouver, BC; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Victoria, BC; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Windsor, ON; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Winnipeg, MB; Research Site:
  
  
• Breast Cancer: National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
  Greenfield Park, PQ; Hopital Charles LeMoyne
  
  
• Breast Cancer: National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
  Montreal, PQ; Sir Mortimer B. Davis - Jewish General Hospital
  
  
• Breast Cancer: National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
  Quebec City, PQ; Hopital du St. Sacrement
  
  
• Breast Cancer: National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
  Toronto, ON; Toronto Sunnybrook Regional Cancer Center
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Calgary, AB; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Kelowna, BC; Research Site:
  
  
• Ovarian Cancer: A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
  Vancouver, BC; Research Site:
  
  
• Ovarian Cancer: National Phase 1 / 2 Ovarian Cancer study investigating the effectiveness and safety of ZK-Epo in combination with Carboplatin in women with platinum-sensitive, recurrent ovarian cancer
  Edmonton; Cross Cancer Institute
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Laval, QC; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Montreal, QC; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Saskatoon, SK; Research Site:
  
  
• Post-Menopausal Osteoporosis: DIVA Study - A Study of Different Regimens of Intravenous Administration of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis
  Toronto, ON; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Calgary, AB; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Quebec City, QC; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Toronto, ON; Research Site:
  
  
• Post-Menopausal Osteoporosis: MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
  Vancouver, BC; Research Site:
  
  
• Urinary Incontinence: A research study for patients with symptoms of overactive bladder
  Victoria, BC; Can-Med Clinical Research Inc.
  
  
• Urinary Incontinence: A research study for patients with symptoms of overactive bladder
  Victoria, BC; Dr. Steinhoff Clinical Research
  
  
• Urinary Incontinence: A research study for patients with symptoms of overactive bladder due to spinal cord injury or multiple sclerosis
  Winnipeg; Rehabilitation Hospital, Health Sciences Centre
  
  

Chile

• Breast Cancer: BETH Study: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy + Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer.
  Santiago; Research Site:
  
  
• Breast Cancer: HERA study - A Study of Intravenous Herceptin (Trastuzumab) in Women With HER2-Positive Primary Breast Cancer
  Santiago; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
  Santiago; Research Site:
  
  
• Post-Menopausal Osteoporosis: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.
  Vina Del Mar; Research Site:
  
  

China

• Breast Cancer: A Continuation Study of Herceptin (Trastuzumab) in Patients With Metastatic Breast Cancer
  Beijing; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) in Women With HER2 Negative Metastatic Breast Cancer
  Beijing; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Beijing; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Chang Sha; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Changchun; Research Center
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Chengdu; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Chongqing; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Hang Zhou; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  He Fei; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Hong Kong; Research Site:
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Nanjing; Research Center
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Shanghai; Research Center
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.
  Suzhou; Research Center
  
  
• Breast Cancer: A Study of Avastin (Bevacizumab) plus Taxane-Based The